Latest Conference Articles
The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.
Real-World Data Support the Frontline Use of Avelumab Plus Axitinib in Advanced RCC
February 15th 2025, 7:33pm
Genitourinary Cancers Symposium (ASCO GU)
The combination of first-line avelumab and axitinib was effective and safe in a real-world analysis of patients with advanced RCC.
Updated Data Support Axitinib Interruption and Avelumab Maintenance After Response in Advanced RCC
February 15th 2025, 7:26pm
Genitourinary Cancers Symposium (ASCO GU)
Updated results further supported the feasibility of VEGFR TKI interruption and immunotherapy maintenance in advanced renal cell carcinoma.
Perioperative Lenvatinib Plus Pembrolizumab Is Safe and Effective in Advanced ccRCC
February 15th 2025, 7:10pm
Genitourinary Cancers Symposium (ASCO GU)
Neoadjuvant lenvatinib plus pembrolizumab followed by adjuvant pembrolizumab was safe and effective in patients with locally advanced, nonmetastatic ccRCC.
Lenvatinib Plus Belzutifan Demonstrates Antitumor Activity in Advanced ccRCC
February 15th 2025, 7:04pm
Genitourinary Cancers Symposium (ASCO GU)
Greater responses were observed in a cohort of patients with renal cell carcinoma receiving lenvatinib plus belzutifan vs pembrolizumab plus lenvatinib.
1.34-mg Dose of Tivozanib Is More Efficacious Than Reduced 0.89-mg Dose in RCC
February 15th 2025, 6:36pm
Genitourinary Cancers Symposium (ASCO GU)
An ER model analysis showed that 1.34 mg of tivozanib provided a greater decrease in tumor size and may be more tolerable than an 0.89-mg dose in RCC.
Orca-T’s Display of Decreased NRM, Increased RFS May Contribute to Favorable OS in Hematologic Malignancies
February 15th 2025, 6:19pm
Transplantation and Cellular Therapy Meetings
Orca-T improved OS vs post-transplant cyclophosphamide in a retrospective analysis of patients with hematologic malignancies.
Perioperative Durvalumab Shows Benefits in MIBC Irrespective of pCR Status
February 15th 2025, 4:51pm
Genitourinary Cancers Symposium (ASCO GU)
Data spotlighted that the addition of perioperative durvalumab to radical cystectomy and adjuvant chemotherapy improved outcomes in MIBC.
Dato-DXd Prolongs Responses in Pretreated Advanced/Metastatic Urothelial Cancer
February 15th 2025, 4:35pm
Dato-DXd generated durable responses and produced no new safety signals in patients with heavily pretreated, locally advanced/metastatic urothelial cancer.
Updated Data Reinforce EV-302 Regimen as SOC in Advanced Urothelial Cancer
February 15th 2025, 4:21pm
Genitourinary Cancers Symposium (ASCO GU)
Enfortumab vedotin plus pembrolizumab maintains compelling benefit over chemotherapy in untreated locally advanced or metastatic urothelial cancer.
Orca-Q Shows Promise in High-Risk Hematologic Cancers and BFT Conditioning May Synergize With the Agent
February 14th 2025, 11:06pm
Transplantation and Cellular Therapy Meetings
One-year follow-up data from an ongoing phase 1 study showed that Orca-Q offered similar benefits as T-cell depletion, without the typical compromises seen.
Avelumab Maintenance Improves OS and PFS in Advanced Urothelial Carcinoma, Regardless of Diabetes Status
February 14th 2025, 10:54pm
Genitourinary Cancers Symposium (ASCO GU)
Avelumab first-line maintenance improved survival outcomes in advanced urothelial carcinoma, regardless of diabetes status.
Obe-Cel Elicits High MRD-Negative Response Rates in R/R B-ALL
February 14th 2025, 10:38pm
Transplantation and Cellular Therapy Meetings
MRD-negative remissions with obe-cel were more durable and associated with higher EFS and OS rates vs MRD-positive remissions in relapsed/refractory B-ALL.
Axatilimab Displays Durable Responses in cGVHD Irrespective of Number of Prior Lines of Treatment
February 14th 2025, 10:34pm
Transplantation and Cellular Therapy Meetings
Axatilimab displayed similar efficacy regardless of the number of prior lines of therapy in chronic graft-versus-host disease.
UGN-102 Induces Clinically Meaningful CR Rates in Low-Grade, Intermediate-Risk NMIBC
February 14th 2025, 10:29pm
Genitourinary Cancers Symposium (ASCO GU)
UGN-102 generated robust, durable responses in patients with low-grade, intermediate-risk NMIBC, in analyses of the phase 3 ENVISION and ATLAS studies.
Dr Albigès on Survival Outcomes With Cabozantinib Plus Nivolumab and Ipilimumab in RCC
February 14th 2025, 10:21pm
Genitourinary Cancers Symposium (ASCO GU)
Laurence Albigès, MD, PhD discusses final OS data and biomarker analyses with cabozantinib plus nivolumab and ipilimumab in intermediate- or poor-risk RCC.
Orca-T With RIC Is Safe in Advanced Hematologic Malignancies
February 14th 2025, 9:57pm
Transplantation and Cellular Therapy Meetings
Orca-T with reduced-intensity conditioning displayed robust and early donor myeloid and T-cell engraftment in advanced hematologic malignancies.
Enfortumab Vedotin/Pembrolizumab Elicits Radiographic Responses in Primary UTUC Lesions
February 14th 2025, 9:35pm
Genitourinary Cancers Symposium (ASCO GU)
Enfortumab vedotin, both as monotherapy and in combination with pembrolizumab, demonstrated clinical activity in patients with UTUC lesions.
Ruxolitinib Plus SOC Prophylaxis Is Associated With Lower Rates of GVHD in Myelofibrosis
February 14th 2025, 9:30pm
Transplantation and Cellular Therapy Meetings
Ruxolitinib plus standard GVHD prophylaxis reduced GVHD in patients with myelofibrosis undergoing transplant.
Updated CheckMate-274 Data Further Support Adjuvant Nivolumab as SOC for High-Risk MIUC
February 14th 2025, 8:44pm
Genitourinary Cancers Symposium (ASCO GU)
Consistent DFS benefit was observed with adjuvant nivolumab vs placebo in all patients with muscle-invasive bladder cancer enrolled in CheckMate-274.